TCGA-A2-A4RY-01A-31R-A266-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 22
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.560
- MYOGENESIS+0.400
- HEDGEHOG_SIGNALING+0.390
- APICAL_JUNCTION+0.340
- TNFA_SIGNALING_VIA_NFKB+0.280
- UV_RESPONSE_DN+0.270
- APICAL_SURFACE+0.250
- P53_PATHWAY+0.250
- KRAS_SIGNALING_DN+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.180
Top 10 suppressed
- E2F_TARGETS-0.660
- MYC_TARGETS_V1-0.630
- G2M_CHECKPOINT-0.600
- OXIDATIVE_PHOSPHORYLATION-0.590
- MTORC1_SIGNALING-0.570
- PROTEIN_SECRETION-0.540
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.420
- GLYCOLYSIS-0.410
- MYC_TARGETS_V2-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A28O-01A-11R-A22K-07 | — | A | 0.950 |
| 2 | R116 | — | — | 0.926 |
| 3 | MBCProject_2661_T2_RNA | — | A | 0.914 |
| 4 | TCGA-D8-A4Z1-01A-21R-A266-07 | — | A | 0.912 |
| 5 | TCGA-A7-A4SC-01A-12R-A266-07 | — | A | 0.898 |
| 6 | TCGA-OL-A5RX-01A-11R-A28M-07 | — | A | 0.896 |
| 7 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.892 |
| 8 | X9cad7a78.ea9b.47b0.9d06.e5e696031cc3 | — | cohortA1 | 0.888 |
| 9 | SRR8613801 | — | A | 0.887 |
| 10 | TCGA-HN-A2OB-01A-21R-A27Q-07 | — | A | 0.881 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.560 | Inavolisib | — uncovered |
| MYOGENESIS | 0.400 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.390 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.340 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.180 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.130 | Inavolisib | — uncovered |
| HYPOXIA | 0.070 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.020 | Remibrutinib | — uncovered |
| COAGULATION | 0.010 | Binimetinib | — uncovered |